2026 Q1 -tulosraportti
Vain PDF
78 päivää sitten
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 20.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 7.5. | ||
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 22.10.2025 | ||
2025 Q2 -tulosraportti 21.8.2025 | ||
2025 Q1 -tulosraportti 8.5.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·7 t sittenastrum 10-10 in germany. Much has been written about Steno supposedly holding back a potential upward revision and that they should even be reported to the financial supervisory authority etc... I think it's time for some realism. Steno has NOT guided on revenue in 2026 and where the revenue should come from! It has been indicated that after the merger of the 2 companies, revenue from 2025 totals 13 Mdkk Furthermore, nothing has been announced about EBITA from 2026... which is much more important than revenue when the cash register is almost empty !!! After Q1 of 2.7 Mdkk, one is already below what was indicated! The average price of Astrum in germany is 600,- dkk and a 30 ml bottle lasts on average 2 months depending on the doctor's dosage. Since the model involves profit sharing with weeco (when it leaves the pharmacy), we can set Steno's share high at 200,- dkk So even with 1000 new patients in germany (if that were to be the case in Q2), there is NOTHING to blame Steno's management for as it has NO influence on the Q2 report .....
- ·2 päivää sittenStock status Privatrezept from 2 to 3 pharmacies that have Weeco Astrum10-10 in stock. Privatrezept primarily sells to private addresses, but also has a collaboration with these three pharmacies, which they also send to, and which have the oil in stock. It is very clear to see that sales in Germany are accelerating, and I have bought many shares in this company, precisely because I have seen, and have shared with you here on Nordnet Social, that many prescriptions are being handed over the counter, and that this has already started in Q2. When we know that, the management also knows it, and if PJ and TS choose first to disclose this to the market, that there has been a much larger sale in Germany than they have announced, at least 3 times, and/or they adjust the financial statements for the entire 2026, on August 20th, then I believe they have violated their disclosure obligation, and I will find an authority that will investigate if this is the case, and that their previous statements are the reason why the share price is at rock bottom.Mojopete, I have apparently not been clear enough, I apologize for that. 1. Stenocare's management has clearly and distinctly informed us investors that there will be no significant revenues from Germany in 2026, which they have repeated several times. They have informed, for example us investors, the following: a) That if there are any revenues from Germany in 2026, it will only be a small amount b. That we as investors should expect that the entire year 2026 in Germany will be a year used to re-register from ADREX to Weeco, something like that. With this information and more that I have accounted for in previous posts, having inserted links earlier, PJ and TS have given the market a very clear impression that we should not expect money from Germany in 2026. These statements are the direct reason why the stock price is at rock bottom. In other words, the above statements are price-manipulating (manipulating is Finanstilsynet's word) BUT I have been hot on the heels of Weeco Pharma since May 13, 2026, and shared everything here on Nordnet social, and what we have been able to ascertain, based on inventory status, is that right from day one, Weeco Pharma had already, at that time, gotten some doctors in their network to prescribe Weeco Astrum 10/10, and since then it has only escalated. What is Stenocare's duty according to Finanstilsynet, and what they will investigate, if Stenocare disregards the legislation, and if it turns out that they have kept internal knowledge to themselves and NOT told the market anything, via a company announcement. When we have the knowledge that Stenocare, after all, is getting revenues from Germany in 2026 that are significantly larger than a small amount, then they must also have the same knowledge. This knowledge is called internal knowledge, and must NOT be kept secret from the stock market. Internal knowledge is as follows: 1. In the moment they found out that Weeco Pharma had actually re-registered Weeco Astrum 10/10 from the old number to the new one, already in Q2, they should have issued a company announcement about this. Because this information would likely affect the stock price upwards. They have clearly and distinctly informed the market that this will not happen in 2026. This information has affected the stock price downwards. 2. As soon as Stenocare could ascertain that doctors had already started prescribing the oil in Q2, and these were also redeemed, they should have informed the market, with a company announcement, that there was already sales of the oil in Germany in Q2, (not how much, because they would not be able to at that time, only that sales have begun) Because this information would likely affect the stock price upwards Because they have informed the market, very clearly and distinctly, that there would be no sales in Germany in 2026, only a small amount, if any sales occurred. This information has affected the stock price downwards. 3) We have been able to ascertain that there has been quite a lot of sales in Germany in Q2, because we know that the oil is a stock item, and it is only that because there is good sales of the oil; if not much oil was sold, it would be an order item. If it turns out that there is so much sales in Germany that the financial statement needs to be adjusted upwards, then they MUST inform the market about this as soon as they find out. They can keep track of how much they send to Germany, which they probably have done, and they also know the exact figures for how much they earn per bottle (they have the tiered model agreement) based on these figures, they can easily calculate that there will be a probability that the financial statement needs to be adjusted upwards. This announcement could sound, for example. According to the legislation, we must inform the market that we can see that significantly more Oils are being sold in Germany than we previously stated, and that the financial statement will therefore be adjusted upwards; as soon as we have knowledge of how much, we will inform about this. Because this information will likely affect the stock price upwards. New company announcement, when they know how much. Again because this information will affect the stock price upwards. The rules are actually quite simple, in this area, for all information that is likely to affect the stock price up or down, is called internal knowledge, and MUST be communicated to us investors immediately when the management of a company obtains this knowledge. As I have previously stated, I only bought many shares in this company because I could see, and have shared with you, that 2026 has already become a valuable market for Stenocare, but because they have NOT complied with the disclosure obligation regarding internal knowledge, the market is not aware that Stenocare is probably worth more than what has been stated currently, because Stenocare has earned more money than they have disclosed to the market. Therefore, I view it with great seriousness that Stenocare has not complied with the disclosure obligation.
- ·3 päivää sitten · MuokattuAn announcement has been issued today, regarding legislation that was just adopted in July. Source from Bundesrat, In the top sections it states that it is not entirely clarified with regard to the people who are undergoing treatment with flower medicine. A little further down you can read that the pharmacies have already anticipated the law change and have sent out letters about the upcoming law change. That is naturally why yesterday we could ascertain that several pharmacies have received Weeco Astrum 10/10 in stock. see under the heading : Current information from health practice https://bdcan.de/cannabisblueten-gkv/
- ·20.7.I have inserted this article, because here it states, in black and white, that those persons who today receive flower medicine, can get a prescription immediately, for cannabis oils. They are not included in the 6-month quarantine. That is also why we can already see that doctors have started to prescribe cannabis oils. There are only 5 months until the subsidy for flower medicine stops. Therefore, I expect that the cannabis shops that only have flowers in their assortment will start to get oils. If you don't want to spend time reading the entire article, you can just read what Dr. Christiane Neubaur, managing director of Verband der Cannabis versorgenden Apotheken (VCA) has said about the above. Dr. Christiane Neubaur, managing director of Verband der Cannabis versorgenden Apotheken (VCA), wrote on LinkedIn: "Many patients who currently receive prescription cannabis medicine do not fall under these approved indications." https://cannabishealthnews.co.uk/2026/07/14/germany-bans-medical-cannabis-flower-from-reimbursement-and-mandates-six-month-trial-for-extracts/I repeat again, again and gladly do it again. The people who have been in a treatment course with Cannabis flowers are beyond the 6 months because they HAVE been in a treatment course with cannabis flowers. The people who have received a prescription for cannabis flowers, but who are not documented as ill, they lose the subsidy and must pay themselves. The people who will be affected, i.e., that they have to wait 6 months before they can get a prescription for ex. Weeco Astrum 10/10, are those who are just entering the treatment system now. Everyone else who has been in treatment systems has completed the 6-month quarantine. The above is the direct reason why we can state today that several pharmacies have received Weeco Astrum 10/10 in stock. As well as we will also see online stores that currently only have flower medicine in their assortment also getting oils and extracts. Either you can scroll down and read what I have written about spin and that it's not about people losing their subsidy. It's only about many people losing a lot of money because flower medicine loses the subsidy, or you can start digging yourself into what is actually happening in Germany.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q1 -tulosraportti
Vain PDF
78 päivää sitten
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·7 t sittenastrum 10-10 in germany. Much has been written about Steno supposedly holding back a potential upward revision and that they should even be reported to the financial supervisory authority etc... I think it's time for some realism. Steno has NOT guided on revenue in 2026 and where the revenue should come from! It has been indicated that after the merger of the 2 companies, revenue from 2025 totals 13 Mdkk Furthermore, nothing has been announced about EBITA from 2026... which is much more important than revenue when the cash register is almost empty !!! After Q1 of 2.7 Mdkk, one is already below what was indicated! The average price of Astrum in germany is 600,- dkk and a 30 ml bottle lasts on average 2 months depending on the doctor's dosage. Since the model involves profit sharing with weeco (when it leaves the pharmacy), we can set Steno's share high at 200,- dkk So even with 1000 new patients in germany (if that were to be the case in Q2), there is NOTHING to blame Steno's management for as it has NO influence on the Q2 report .....
- ·2 päivää sittenStock status Privatrezept from 2 to 3 pharmacies that have Weeco Astrum10-10 in stock. Privatrezept primarily sells to private addresses, but also has a collaboration with these three pharmacies, which they also send to, and which have the oil in stock. It is very clear to see that sales in Germany are accelerating, and I have bought many shares in this company, precisely because I have seen, and have shared with you here on Nordnet Social, that many prescriptions are being handed over the counter, and that this has already started in Q2. When we know that, the management also knows it, and if PJ and TS choose first to disclose this to the market, that there has been a much larger sale in Germany than they have announced, at least 3 times, and/or they adjust the financial statements for the entire 2026, on August 20th, then I believe they have violated their disclosure obligation, and I will find an authority that will investigate if this is the case, and that their previous statements are the reason why the share price is at rock bottom.Mojopete, I have apparently not been clear enough, I apologize for that. 1. Stenocare's management has clearly and distinctly informed us investors that there will be no significant revenues from Germany in 2026, which they have repeated several times. They have informed, for example us investors, the following: a) That if there are any revenues from Germany in 2026, it will only be a small amount b. That we as investors should expect that the entire year 2026 in Germany will be a year used to re-register from ADREX to Weeco, something like that. With this information and more that I have accounted for in previous posts, having inserted links earlier, PJ and TS have given the market a very clear impression that we should not expect money from Germany in 2026. These statements are the direct reason why the stock price is at rock bottom. In other words, the above statements are price-manipulating (manipulating is Finanstilsynet's word) BUT I have been hot on the heels of Weeco Pharma since May 13, 2026, and shared everything here on Nordnet social, and what we have been able to ascertain, based on inventory status, is that right from day one, Weeco Pharma had already, at that time, gotten some doctors in their network to prescribe Weeco Astrum 10/10, and since then it has only escalated. What is Stenocare's duty according to Finanstilsynet, and what they will investigate, if Stenocare disregards the legislation, and if it turns out that they have kept internal knowledge to themselves and NOT told the market anything, via a company announcement. When we have the knowledge that Stenocare, after all, is getting revenues from Germany in 2026 that are significantly larger than a small amount, then they must also have the same knowledge. This knowledge is called internal knowledge, and must NOT be kept secret from the stock market. Internal knowledge is as follows: 1. In the moment they found out that Weeco Pharma had actually re-registered Weeco Astrum 10/10 from the old number to the new one, already in Q2, they should have issued a company announcement about this. Because this information would likely affect the stock price upwards. They have clearly and distinctly informed the market that this will not happen in 2026. This information has affected the stock price downwards. 2. As soon as Stenocare could ascertain that doctors had already started prescribing the oil in Q2, and these were also redeemed, they should have informed the market, with a company announcement, that there was already sales of the oil in Germany in Q2, (not how much, because they would not be able to at that time, only that sales have begun) Because this information would likely affect the stock price upwards Because they have informed the market, very clearly and distinctly, that there would be no sales in Germany in 2026, only a small amount, if any sales occurred. This information has affected the stock price downwards. 3) We have been able to ascertain that there has been quite a lot of sales in Germany in Q2, because we know that the oil is a stock item, and it is only that because there is good sales of the oil; if not much oil was sold, it would be an order item. If it turns out that there is so much sales in Germany that the financial statement needs to be adjusted upwards, then they MUST inform the market about this as soon as they find out. They can keep track of how much they send to Germany, which they probably have done, and they also know the exact figures for how much they earn per bottle (they have the tiered model agreement) based on these figures, they can easily calculate that there will be a probability that the financial statement needs to be adjusted upwards. This announcement could sound, for example. According to the legislation, we must inform the market that we can see that significantly more Oils are being sold in Germany than we previously stated, and that the financial statement will therefore be adjusted upwards; as soon as we have knowledge of how much, we will inform about this. Because this information will likely affect the stock price upwards. New company announcement, when they know how much. Again because this information will affect the stock price upwards. The rules are actually quite simple, in this area, for all information that is likely to affect the stock price up or down, is called internal knowledge, and MUST be communicated to us investors immediately when the management of a company obtains this knowledge. As I have previously stated, I only bought many shares in this company because I could see, and have shared with you, that 2026 has already become a valuable market for Stenocare, but because they have NOT complied with the disclosure obligation regarding internal knowledge, the market is not aware that Stenocare is probably worth more than what has been stated currently, because Stenocare has earned more money than they have disclosed to the market. Therefore, I view it with great seriousness that Stenocare has not complied with the disclosure obligation.
- ·3 päivää sitten · MuokattuAn announcement has been issued today, regarding legislation that was just adopted in July. Source from Bundesrat, In the top sections it states that it is not entirely clarified with regard to the people who are undergoing treatment with flower medicine. A little further down you can read that the pharmacies have already anticipated the law change and have sent out letters about the upcoming law change. That is naturally why yesterday we could ascertain that several pharmacies have received Weeco Astrum 10/10 in stock. see under the heading : Current information from health practice https://bdcan.de/cannabisblueten-gkv/
- ·20.7.I have inserted this article, because here it states, in black and white, that those persons who today receive flower medicine, can get a prescription immediately, for cannabis oils. They are not included in the 6-month quarantine. That is also why we can already see that doctors have started to prescribe cannabis oils. There are only 5 months until the subsidy for flower medicine stops. Therefore, I expect that the cannabis shops that only have flowers in their assortment will start to get oils. If you don't want to spend time reading the entire article, you can just read what Dr. Christiane Neubaur, managing director of Verband der Cannabis versorgenden Apotheken (VCA) has said about the above. Dr. Christiane Neubaur, managing director of Verband der Cannabis versorgenden Apotheken (VCA), wrote on LinkedIn: "Many patients who currently receive prescription cannabis medicine do not fall under these approved indications." https://cannabishealthnews.co.uk/2026/07/14/germany-bans-medical-cannabis-flower-from-reimbursement-and-mandates-six-month-trial-for-extracts/I repeat again, again and gladly do it again. The people who have been in a treatment course with Cannabis flowers are beyond the 6 months because they HAVE been in a treatment course with cannabis flowers. The people who have received a prescription for cannabis flowers, but who are not documented as ill, they lose the subsidy and must pay themselves. The people who will be affected, i.e., that they have to wait 6 months before they can get a prescription for ex. Weeco Astrum 10/10, are those who are just entering the treatment system now. Everyone else who has been in treatment systems has completed the 6-month quarantine. The above is the direct reason why we can state today that several pharmacies have received Weeco Astrum 10/10 in stock. As well as we will also see online stores that currently only have flower medicine in their assortment also getting oils and extracts. Either you can scroll down and read what I have written about spin and that it's not about people losing their subsidy. It's only about many people losing a lot of money because flower medicine loses the subsidy, or you can start digging yourself into what is actually happening in Germany.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 20.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 7.5. | ||
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 22.10.2025 | ||
2025 Q2 -tulosraportti 21.8.2025 | ||
2025 Q1 -tulosraportti 8.5.2025 |
2026 Q1 -tulosraportti
Vain PDF
78 päivää sitten
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 20.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 7.5. | ||
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 22.10.2025 | ||
2025 Q2 -tulosraportti 21.8.2025 | ||
2025 Q1 -tulosraportti 8.5.2025 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·7 t sittenastrum 10-10 in germany. Much has been written about Steno supposedly holding back a potential upward revision and that they should even be reported to the financial supervisory authority etc... I think it's time for some realism. Steno has NOT guided on revenue in 2026 and where the revenue should come from! It has been indicated that after the merger of the 2 companies, revenue from 2025 totals 13 Mdkk Furthermore, nothing has been announced about EBITA from 2026... which is much more important than revenue when the cash register is almost empty !!! After Q1 of 2.7 Mdkk, one is already below what was indicated! The average price of Astrum in germany is 600,- dkk and a 30 ml bottle lasts on average 2 months depending on the doctor's dosage. Since the model involves profit sharing with weeco (when it leaves the pharmacy), we can set Steno's share high at 200,- dkk So even with 1000 new patients in germany (if that were to be the case in Q2), there is NOTHING to blame Steno's management for as it has NO influence on the Q2 report .....
- ·2 päivää sittenStock status Privatrezept from 2 to 3 pharmacies that have Weeco Astrum10-10 in stock. Privatrezept primarily sells to private addresses, but also has a collaboration with these three pharmacies, which they also send to, and which have the oil in stock. It is very clear to see that sales in Germany are accelerating, and I have bought many shares in this company, precisely because I have seen, and have shared with you here on Nordnet Social, that many prescriptions are being handed over the counter, and that this has already started in Q2. When we know that, the management also knows it, and if PJ and TS choose first to disclose this to the market, that there has been a much larger sale in Germany than they have announced, at least 3 times, and/or they adjust the financial statements for the entire 2026, on August 20th, then I believe they have violated their disclosure obligation, and I will find an authority that will investigate if this is the case, and that their previous statements are the reason why the share price is at rock bottom.Mojopete, I have apparently not been clear enough, I apologize for that. 1. Stenocare's management has clearly and distinctly informed us investors that there will be no significant revenues from Germany in 2026, which they have repeated several times. They have informed, for example us investors, the following: a) That if there are any revenues from Germany in 2026, it will only be a small amount b. That we as investors should expect that the entire year 2026 in Germany will be a year used to re-register from ADREX to Weeco, something like that. With this information and more that I have accounted for in previous posts, having inserted links earlier, PJ and TS have given the market a very clear impression that we should not expect money from Germany in 2026. These statements are the direct reason why the stock price is at rock bottom. In other words, the above statements are price-manipulating (manipulating is Finanstilsynet's word) BUT I have been hot on the heels of Weeco Pharma since May 13, 2026, and shared everything here on Nordnet social, and what we have been able to ascertain, based on inventory status, is that right from day one, Weeco Pharma had already, at that time, gotten some doctors in their network to prescribe Weeco Astrum 10/10, and since then it has only escalated. What is Stenocare's duty according to Finanstilsynet, and what they will investigate, if Stenocare disregards the legislation, and if it turns out that they have kept internal knowledge to themselves and NOT told the market anything, via a company announcement. When we have the knowledge that Stenocare, after all, is getting revenues from Germany in 2026 that are significantly larger than a small amount, then they must also have the same knowledge. This knowledge is called internal knowledge, and must NOT be kept secret from the stock market. Internal knowledge is as follows: 1. In the moment they found out that Weeco Pharma had actually re-registered Weeco Astrum 10/10 from the old number to the new one, already in Q2, they should have issued a company announcement about this. Because this information would likely affect the stock price upwards. They have clearly and distinctly informed the market that this will not happen in 2026. This information has affected the stock price downwards. 2. As soon as Stenocare could ascertain that doctors had already started prescribing the oil in Q2, and these were also redeemed, they should have informed the market, with a company announcement, that there was already sales of the oil in Germany in Q2, (not how much, because they would not be able to at that time, only that sales have begun) Because this information would likely affect the stock price upwards Because they have informed the market, very clearly and distinctly, that there would be no sales in Germany in 2026, only a small amount, if any sales occurred. This information has affected the stock price downwards. 3) We have been able to ascertain that there has been quite a lot of sales in Germany in Q2, because we know that the oil is a stock item, and it is only that because there is good sales of the oil; if not much oil was sold, it would be an order item. If it turns out that there is so much sales in Germany that the financial statement needs to be adjusted upwards, then they MUST inform the market about this as soon as they find out. They can keep track of how much they send to Germany, which they probably have done, and they also know the exact figures for how much they earn per bottle (they have the tiered model agreement) based on these figures, they can easily calculate that there will be a probability that the financial statement needs to be adjusted upwards. This announcement could sound, for example. According to the legislation, we must inform the market that we can see that significantly more Oils are being sold in Germany than we previously stated, and that the financial statement will therefore be adjusted upwards; as soon as we have knowledge of how much, we will inform about this. Because this information will likely affect the stock price upwards. New company announcement, when they know how much. Again because this information will affect the stock price upwards. The rules are actually quite simple, in this area, for all information that is likely to affect the stock price up or down, is called internal knowledge, and MUST be communicated to us investors immediately when the management of a company obtains this knowledge. As I have previously stated, I only bought many shares in this company because I could see, and have shared with you, that 2026 has already become a valuable market for Stenocare, but because they have NOT complied with the disclosure obligation regarding internal knowledge, the market is not aware that Stenocare is probably worth more than what has been stated currently, because Stenocare has earned more money than they have disclosed to the market. Therefore, I view it with great seriousness that Stenocare has not complied with the disclosure obligation.
- ·3 päivää sitten · MuokattuAn announcement has been issued today, regarding legislation that was just adopted in July. Source from Bundesrat, In the top sections it states that it is not entirely clarified with regard to the people who are undergoing treatment with flower medicine. A little further down you can read that the pharmacies have already anticipated the law change and have sent out letters about the upcoming law change. That is naturally why yesterday we could ascertain that several pharmacies have received Weeco Astrum 10/10 in stock. see under the heading : Current information from health practice https://bdcan.de/cannabisblueten-gkv/
- ·20.7.I have inserted this article, because here it states, in black and white, that those persons who today receive flower medicine, can get a prescription immediately, for cannabis oils. They are not included in the 6-month quarantine. That is also why we can already see that doctors have started to prescribe cannabis oils. There are only 5 months until the subsidy for flower medicine stops. Therefore, I expect that the cannabis shops that only have flowers in their assortment will start to get oils. If you don't want to spend time reading the entire article, you can just read what Dr. Christiane Neubaur, managing director of Verband der Cannabis versorgenden Apotheken (VCA) has said about the above. Dr. Christiane Neubaur, managing director of Verband der Cannabis versorgenden Apotheken (VCA), wrote on LinkedIn: "Many patients who currently receive prescription cannabis medicine do not fall under these approved indications." https://cannabishealthnews.co.uk/2026/07/14/germany-bans-medical-cannabis-flower-from-reimbursement-and-mandates-six-month-trial-for-extracts/I repeat again, again and gladly do it again. The people who have been in a treatment course with Cannabis flowers are beyond the 6 months because they HAVE been in a treatment course with cannabis flowers. The people who have received a prescription for cannabis flowers, but who are not documented as ill, they lose the subsidy and must pay themselves. The people who will be affected, i.e., that they have to wait 6 months before they can get a prescription for ex. Weeco Astrum 10/10, are those who are just entering the treatment system now. Everyone else who has been in treatment systems has completed the 6-month quarantine. The above is the direct reason why we can state today that several pharmacies have received Weeco Astrum 10/10 in stock. As well as we will also see online stores that currently only have flower medicine in their assortment also getting oils and extracts. Either you can scroll down and read what I have written about spin and that it's not about people losing their subsidy. It's only about many people losing a lot of money because flower medicine loses the subsidy, or you can start digging yourself into what is actually happening in Germany.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt